The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy and Safety of Renal Tubule Cell Therapy for Acute Renal Failure
Open accessAbstract
The mortality rate for patients with acute renal failure (ARF) remains unacceptably high. Although dialysis removes waste products and corrects fluid imbalance, it does not perform the absorptive, metabolic, endocrine, and immunologic functions of normal renal tubule cells. The renal tubule assist device (RAD) is composed of a conventional hemofilter lined by monolayers of renal cells. For testing whether short-term (up to 72 h) treatment with the RAD would improve survival in patients with ARF compared with conventional continuous renal replacement therapy (CRRT), a Phase II, multicenter, randomized, controlled, open-label trial involving 58 patients who had ARF and required CRRT was performed. Forty patients received continuous venovenous hemofiltration + RAD, and 18 received CRRT alone. The primary efficacy end point was all-cause mortality at 28 d; additional end points included all-cause mortality at 90 and 180 d, time to recovery of renal function, time to intensive care unit and hospital discharge, and safety. At day 28, the mortality rate was 33% in the RAD group and 61% in the CRRT group. Kaplan-Meier analysis revealed that survival through day 180 was significantly improved in the RAD group, and Cox proportional hazards models suggested that the risk for death was approximately 50% of that observed in the CRRT-alone group. RAD therapy was also associated with more rapid recovery of kidney function, was well tolerated, and had the expected adverse event profile for critically ill patients with ARF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Cited by
Bellomo, R., Kellum, J. A., & Ronco, C. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61454-2 · Cited by 2,598
Calzavacca, P., Licari, E., & Bellomo, R. (2010) · Surgical Intensive Care Medicine · doi:10.1007/978-0-387-77893-8_38 · Cited by 533
The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer?
Boomer, J. S., Green, J. M., & Hotchkiss, R. S. (2014) · Virulence · doi:10.4161/viru.26516 · Cited by 317
High-Molecular Weight Iron Dextran: A Wolf in Sheep's Clothing?
Rodgers, G. M., Auerbach, M., Cella, D., Chertow, G. M., Coyne, D. W., Glaspy, J. A., & Henry, D. H. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008030255 · Cited by 56
Zha, J., Li, C., Cheng, G., Huang, L., Bai, Z., & Fang, C. (2019) · Medicine · doi:10.1097/md.0000000000015257 · Cited by 15
Metadata
- Authors
- Tumlin, J., Wali, R., Williams, W., Murray, P., Tolwani, A. J., Vinnikova, A. K., Szerlip, H. M., Ye, J., Paganini, E. P., Dworkin, L., Finkel, K. W., Kraus, M. A., & Humes, H. D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2008-05
- Volume
- 19
- Issue
- 5
- Pages
- 1034-1040
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2054641153
- Cited by
- 214
- References
- 1
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Renal Tubule Cell Therapy for Acute Renal Failure. https://app.cochat.ai/papers/10.1681/asn.2007080895
- The paper
- Tumlin, J., Wali, R., Williams, W., Murray, P., Tolwani, A. J., Vinnikova, A. K., Szerlip, H. M., Ye, J., Paganini, E. P., Dworkin, L., Finkel, K. W., Kraus, M. A., & Humes, H. D. (2008). Efficacy and Safety of Renal Tubule Cell Therapy for Acute Renal Failure. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2007080895
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.